Are You Interested in Starting Your Own Health Related Home Based Business? Please Click Here to Find Out How!

Lapatinib used in tandem with paclitaxel demonstrates significant clinical activity in HER2-overexpressing (HER2+) patients with metastatic breast cancer, according to results released today at the 14th European Cancer Conference (ECCO). Lapatinib is an oral tyrosine kinase inhibitor of EGFR/HER2 that was recently approved in the U.S. [click link for full article]

More: continued here